Tizona Therapeutics is a clinical-stage biotechnology company focused on developing first-in-class cancer immunotherapies by translating novel scientific insights into new medicines. Its lead program, TTX-080, is a first-in-class HLA-G antagonist in clinical trials for advanced solid tumors. Tizona is a portfolio company of Canaan Partners. - View it on GitHub